CA3020387C - Hydroxamate triterpenoid derivatives - Google Patents

Hydroxamate triterpenoid derivatives Download PDF

Info

Publication number
CA3020387C
CA3020387C CA3020387A CA3020387A CA3020387C CA 3020387 C CA3020387 C CA 3020387C CA 3020387 A CA3020387 A CA 3020387A CA 3020387 A CA3020387 A CA 3020387A CA 3020387 C CA3020387 C CA 3020387C
Authority
CA
Canada
Prior art keywords
hydroxy
pharmaceutically acceptable
amide
carbon
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3020387A
Other languages
English (en)
French (fr)
Other versions
CA3020387A1 (en
Inventor
Eduardo Munoz Blanco
Alberto MINASSI
Maria Luz Bellido Cabello De Alba
Giovanni Appendino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivacell Biotechnology Espana SL
Original Assignee
Vivacell Biotechnology Espana SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivacell Biotechnology Espana SL filed Critical Vivacell Biotechnology Espana SL
Publication of CA3020387A1 publication Critical patent/CA3020387A1/en
Application granted granted Critical
Publication of CA3020387C publication Critical patent/CA3020387C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3020387A 2016-10-13 2017-10-03 Hydroxamate triterpenoid derivatives Active CA3020387C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16193684.4 2016-10-13
EP16193684 2016-10-13
PCT/EP2017/075042 WO2018069086A1 (en) 2016-10-13 2017-10-03 Hydroxamate triterpenoid derivatives

Publications (2)

Publication Number Publication Date
CA3020387A1 CA3020387A1 (en) 2018-04-19
CA3020387C true CA3020387C (en) 2020-07-28

Family

ID=57136723

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020387A Active CA3020387C (en) 2016-10-13 2017-10-03 Hydroxamate triterpenoid derivatives

Country Status (14)

Country Link
US (1) US10766855B2 (https=)
EP (1) EP3365351B1 (https=)
JP (1) JP6598224B2 (https=)
KR (1) KR102038930B1 (https=)
CN (1) CN108368150B (https=)
AU (1) AU2017341257B2 (https=)
BR (1) BR112018068996A2 (https=)
CA (1) CA3020387C (https=)
ES (1) ES2774198T3 (https=)
HK (1) HK1254200A1 (https=)
IL (1) IL259391B (https=)
MX (2) MX364919B (https=)
RU (1) RU2018136782A (https=)
WO (1) WO2018069086A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020157494A1 (en) * 2019-01-30 2020-08-06 Rothamsted Research Ltd Cylodimer of dehydrosalicortin and derivatives thereof isolated from plant of the genus salix for use in cancer therapy
CN114805469A (zh) * 2021-01-27 2022-07-29 中国科学院上海药物研究所 含吡唑的白桦脂酸类衍生物，其制备方法及用途
CN117567544A (zh) * 2021-04-27 2024-02-20 中国医学科学院药物研究所 一类具有α,β-不饱和酮结构五环三萜类化合物在预防和治疗神经退行性疾病中的用途
WO2024145502A1 (en) * 2022-12-29 2024-07-04 The Board Of Regents Of The University Of Texas System Synthetic triterpenoids and compositions thereof in weight management, skeletal muscle function, and appetite suppression
CN119504913B (zh) * 2024-11-18 2025-09-26 南京中医药大学 一类五环三萜衍生物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002322068A (ja) * 2001-02-26 2002-11-08 Japan Science & Technology Corp 血管再生促進剤
KR100821649B1 (ko) * 2006-01-24 2008-04-11 서울시립대학교 산학협력단 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
CN101367861A (zh) * 2007-08-15 2009-02-18 中国药科大学 2-羟基-3-脱氧五环三萜类化合物及其衍生物、其制备方法及用途
PL2252283T3 (pl) * 2008-01-11 2019-09-30 Reata Pharmaceuticals, Inc. Syntetyczne triterpenoidy i sposoby zastosowania w leczeniu choroby
WO2009146216A2 (en) * 2008-04-18 2009-12-03 Reata Pharmaceuticals. Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US20100144688A1 (en) * 2008-12-10 2010-06-10 Advanced Life Sciences, Inc. 23-Substituted Derivatives of Lupane-type Pentacyclic Triterpenoids
KR101811462B1 (ko) * 2010-01-11 2018-01-25 피닉스 바이오테크놀러지 인코포레이티드. 협죽도 추출물을 포함하는 신경질환 치료용 조성물
CN102180939B (zh) 2011-03-30 2013-02-20 沈阳化工大学 一种抗肿瘤活性的熊果酸化学修饰物及其制备方法
US8324264B1 (en) * 2011-07-22 2012-12-04 Sequoia Sciences, Inc. Inhibitors of bacterial biofilms and related methods
CN102499925B (zh) * 2011-10-21 2015-11-11 上海中医药大学 一种中性粒细胞弹性蛋白酶抑制剂

Also Published As

Publication number Publication date
KR102038930B1 (ko) 2019-11-05
AU2017341257A1 (en) 2018-11-01
AU2017341257B2 (en) 2019-08-08
IL259391A (en) 2018-07-31
MX2019005448A (es) 2019-07-04
CN108368150A (zh) 2018-08-03
RU2018136782A (ru) 2020-04-20
US10766855B2 (en) 2020-09-08
WO2018069086A1 (en) 2018-04-19
MX2018006429A (es) 2018-09-27
IL259391B (en) 2019-10-31
RU2018136782A3 (https=) 2020-04-20
BR112018068996A2 (pt) 2019-01-22
KR20180117700A (ko) 2018-10-29
ES2774198T3 (es) 2020-07-17
EP3365351B1 (en) 2019-12-04
EP3365351A1 (en) 2018-08-29
CN108368150B (zh) 2022-02-25
US20190367447A1 (en) 2019-12-05
CA3020387A1 (en) 2018-04-19
JP6598224B2 (ja) 2019-10-30
MX364919B (es) 2019-05-13
JP2019519464A (ja) 2019-07-11
HK1254200A1 (zh) 2019-07-12

Similar Documents

Publication Publication Date Title
CA3020387C (en) Hydroxamate triterpenoid derivatives
KR102101774B1 (ko) 바독솔론 메틸의 2,2-다이플루오로프로피온아미드 유도체, 그의 다형태 및 사용 방법
Moreau et al. A novel pregnane X receptor and S14‐mediated lipogenic pathway in human hepatocyte
CN106103452B (zh) 皮质抑素类似物及其合成和用途
AU2017356955B2 (en) Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
EP2959918B1 (en) Anti-malignant tumor agent composition
JP5598775B2 (ja) 癌の介入治療および根絶のためのｉｔｅとその類似体を含む医薬組成物
EP3830103B1 (en) Fluorinated bile acid derivatives
Varghese et al. Polyaminohydroxamic acids and polyaminobenzamides as isoform selective histone deacetylase inhibitors
EP2913321B1 (en) Novel cannabigerol derivatives
US20210317070A1 (en) Cannabidiol derivatives as inhibitors of the hif prolyl hydroxylases activity
Zuo et al. Design, synthesis and biological evaluation of novel arylpropionic esters for the treatment of acute kidney injury
Yang et al. Design, Semi-Synthesis, and Antibacterial Activities of Triterpenoid-Hydrazone Conjugates
EP3353186B1 (en) Highly efficient nrf2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
US20200206234A1 (en) Isoxazole derivatives as inducers of fetal hemoglobin in erythroid precursor cells from beta-thalassemic patients
JP2013043874A (ja) チューブリン結合剤
HK40055914B (en) Fluorinated bile acid derivatives
HK40055914A (en) Fluorinated bile acid derivatives
Belostotskaja et al. On the Effect of Substitutes on Phenol Toxicity
HK1229783B (zh) 新大麻萜酚衍生物
EP2188301A2 (en) Novel steroidal esters of 17-oximino-5-androsten-3 beta-ol

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240927

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240927

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240927

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250916